GZR18

Phase 3Small molecule

GGan & Lee Pharmaceuticals.

GZR18 is one of 121 small molecule programs targeting Type 2 Diabetes Mellitus. It is currently in Phase 3.

Indications

Total Trials

Active Trials

120

Competitors

Pipeline

Status by Indication[3][1]

Indication

Type 2 Diabetes MellitusActive, not recruiting

Obstructive Sleep ApneaActive, not recruiting

Weight LossActive, not recruiting

Type 2 Diabetes MellitusPhase 2

Active, not recruiting

Obstructive Sleep ApneaPhase 3

Active, not recruiting

Weight LossPhase 3

Active, not recruiting

Competition

Competitive Landscape

676 competitors in Type 2 Diabetes Mellitus

#DrugCompanyPhaseTrials

GZR18

GGan & Lee Pharmaceuticals.

Phase 3

5 2

Byetta

AstraZeneca

Preclinical

20 3

Tanzeum

GSK

Preclinical

10 4

Insulin 320

Novo Nordisk

Preclinical

43 5

Adenocard

Astellas

Preclinical

1 6

NOVOLIN R

Novo Nordisk

Preclinical

1 7

Cipro

Myrbetriq

Dostinex

Golytely

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 3Active, not recruiting

Type 2 Diabetes Mellitus

NCT06778967

Q1 2027

Phase 2Active, not recruiting

Type 2 Diabetes Mellitus

NCT07055386

Phase 1Recruiting

Function

NCT07144098

Phase 3Active, not recruiting

Type 2 Diabetes Mellitus

NCT06777238

Q2 2027

Phase 3Recruiting

Overweight

NCT07150975

Q4 2027

Phase 3Recruiting

Weight Loss

NCT07292441

Clinical

Trials by Indication[1]

Overweight7 trials

A Phase III Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Adult Obese/Overweight Subjects

Active, not recruiting·GGan & Lee Pharmaceuticals.·Phase 3·NCT06728124·630 enrolled

A Phase I Study to Evaluate the PK and PD Profiles of GZR102 Injection Versus GZR4 Injection and GZR18 Injection Given Separately in Chinese Adult Overweight Subjects

Not yet recruiting·GGan & Lee Pharmaceuticals.·Phase 1·NCT06974487·30 enrolled

Efficacy and Safety of GZR18 Every 2 Weeks Versus Tirzepatide and Placebo in Obese or Overweight Participants

Not yet recruiting·GGan and Lee Pharmaceuticals, USA·Phase 2·NCT06737042·285 enrolled

Show 4 more trials

Phase III Clinical Study Comparing the Efficacy and Safety of GZR18 Injection and Semaglutide (Wegovy®) in Adult Obese or Overweight Subjects

Recruiting·GGan & Lee Pharmaceuticals.·Phase 3·NCT07150975·420 enrolled

A Study of GZR18 Injection in Obese/Overweight Patients

Completed·GGan and Lee Pharmaceuticals, USA·Phase 2·NCT06256562·340 enrolled

A Study of GZR18 Injection in Chinese Obese/Overweight Patients

Completed·GGan and Lee Pharmaceuticals, USA·Phase 1/2·NCT06256536·60 enrolled

A Phase I Study of GZR18 Injection in Obese/Overweight Subjects

Completed·GGan and Lee Pharmaceuticals, USA·Phase 1·NCT06548945·16 enrolled

Type 2 Diabetes Mellitus5 trials

A Phase III Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Subjects With Type 2 Diabetes Mellitus and Poor Blood Glucose Control by Diet and Exercise

Active, not recruiting·GGan & Lee Pharmaceuticals.·Phase 3·NCT06777238·274 enrolled

A Study of GZR18 Injection in Chinese Adult Patients With Type 2 Diabetes Mellitus (T2DM)

Completed·GGan and Lee Pharmaceuticals, USA·Phase 1/2·NCT06256523·72 enrolled

A Study of GZR18 Injection in Chinese Patients With Type 2 Diabetes Mellitus

Unknown status·GGan and Lee Pharmaceuticals, USA·Phase 2·NCT06256549·272 enrolled

Show 2 more trials

A Study to Compare the Efficacy and Safety of GZR102 Injection and GZR18 Injection in Type 2 Diabetes Mellitus

Active, not recruiting·GGan & Lee Pharmaceuticals.·Phase 2·NCT07055386·90 enrolled

A Phase III Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Adult Type 2 Diabetes Mellitus

Active, not recruiting·GGan & Lee Pharmaceuticals.·Phase 3·NCT06778967·1,100 enrolled

Function1 trial

Study of Pharmacokinetics and Safety of GZR18 Injection in Subjects With Liver Insufficiency and Normal Liver Function

Recruiting·GGan & Lee Pharmaceuticals.·Phase 1·NCT07144098·24 enrolled

Renal Impairment1 trial

Study of Pharmacokinetics and Safety of GZR18 Injection in Subjects With Renal Impairment and Normal Renal Function

Recruiting·GGan & Lee Pharmaceuticals.·Phase 1·NCT07141030·32 enrolled

Obstructive Sleep Apnea1 trial

A Phase III Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Obese Subjects With Obstructive Sleep Apnea Not Treated With Positive Airway Pressure (PAP) Therapy

Not yet recruiting·GGan & Lee Pharmaceuticals.·Phase 3·NCT07493057·140 enrolled

2 more indications

Weight loss1 trial

Extension Study of the Phase 3 Clinical Study of GZR18 Injection for Weight Loss

Recruiting·GGan & Lee Pharmaceuticals.·Phase 3·NCT07292441·500 enrolled

Unspecified4 trials

The Study of [14C] GZR18

Completed·GGan & Lee Pharmaceuticals.·Phase 1·NCT07119450·6 enrolled

Bioequivalence Study of GZR18 Injection Before and After CMC Change

Recruiting·GGan & Lee Pharmaceuticals.·Phase 1·NCT07355738·138 enrolled

A Study of GZR18 Tablet in Chinese Healthy Subjects

Active, not recruiting·GGan and Lee Pharmaceuticals, USA·Phase 1·NCT06554054·92 enrolled

Show 1 more trial

A Phase I Study of GZR18 Injection in Healthy Subjects

Completed·GGan and Lee Pharmaceuticals, USA·Phase 1·NCT06548997·57 enrolled

Sources

References

[1]
ClinicalTrials.gov — 20 trial records for GZR18. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — GZR18 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for GZR18. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Gan & Lee Pharmaceuticals. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: GGan & Lee Pharmaceuticals.

GZR18

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q1 2027

Q2 2027

Q4 2027

Trials by Indication[1]

Overweight7 trials

Type 2 Diabetes Mellitus5 trials

Function1 trial

Renal Impairment1 trial

Obstructive Sleep Apnea1 trial

Weight loss1 trial

Unspecified4 trials

References

Drug Info

Quick Facts

Related News